FDA Refers Several Full Disclosure, Insider Trading Violations To SEC
This article was originally published in The Pink Sheet Daily
Executive Summary
More than half a dozen FDA-referred cases are under investigation at the Securities & Exchange Commission, official says. FDA is “struggling” to provide SEC with full disclosure support without jeopardizing confidential proprietary information. Three of the six cases also involve insider trading.